01 / Contract Profile
75F40119C10139 Federal Contract Award
Agency code 7524
PERFORMANCE OF STUDY ENTITLED "MIDD APPROACH TO IDENTIFY CRITICAL QUALITY ATTRIBUTES AND SPECIFICATIONS FOR GENERIC NANOTECHNOLOGY PRODUCTS."
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75F40119C10139 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations-$130.2K
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2019 | $447.2K | 1 | — |
| FY 2020 | $263.1K | 2 | −41.2% |
| FY 2021 | $703.3K | 2 | +167.3% |
| FY 2022 | $0 | 1 | −100.0% |
| FY 2023 | $490.7K | 2 | — |
| FY 2024 | $0 | 2 | −100.0% |
| FY 2026 | -$130.2K | 1 | — |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | FOOD AND DRUG ADMINISTRATION | FDA OFFICE OF ACQ GRANT SVCS |
05 / Contractor
Who holds this federal contract?
INSTITUTE OF QUANTITATIVE SYSTEMS PHARMACOLOGY
UEI KUD8J8K9UZY5 · CAGE 7ZVB1
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541715 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) | $1.77M | 11 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AJ11 | GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $1.77M | 11 | 100.0% |
08 / Place of Performance
Where is the work recorded?
CARLSBAD, SAN DIEGO, CALIFORNIA, UNITED STATES
ZIP 920087340
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Jul 12, 2026 | P00010 | -$130.2K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Jul 9, 2024 | P00009 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Mar 20, 2024 | P00008 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Aug 1, 2023 | P00007 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| May 5, 2023 | P00006 | $490.7K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Aug 26, 2022 | P00005 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Dec 14, 2021 | P00004 | $516.9K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Apr 23, 2021 | P00003 | $186.4K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Dec 24, 2020 | P00002 | $263.1K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Jun 15, 2020 | P00001 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
| Sep 25, 2019 | Base action | $447.2K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AJ11 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.